If approved, mCOMBRIAX would become the first combination Covid-flu jab to gain regulatory approval anywhere across the globe.
Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
The combined cash balance at closing is projected to fund operations through 2030.
Yuviwel’s approval marks a more convenient option compared to BioMarin’s daily injection Voxzogo.
The CHMP’s recommendation is based on LIBERTY-CUPID data, including two Phase III and the CUPIDKids studies.
